

www.tajpharma.com

It is used with:

Capecitabine in women with HER2 positive (HER2+) breast cancer whose disease has not gotten better with other chemotherapy.

Letrozole in postmenopausal women with HER2+ and hormone receptor-positive (HR+) breast cancer who need hormone therapy.

Ultoxima®
Lapatinib Ditosylate
TABLETS 250mg

Ultoxima® Lapatinib ditosylate is approved to be used with other drugs to treat: Breast cancer that is advanced or has metastasized (spread to other parts of the body).

QUALITATIVE AND QUANTITATIVE COMPOSITION

Each film-coated tablet contains:

405 mg of lapatinib ditosylate IP, equivalent to 250 mg lapatinib.

Colours: Ferric Oxide USPNF & Titanium Dioxide IP.

Lapatinib ditosylate tablets are oval, biconvex, yellow, film-coated tablets, with one side plain and the opposite side debossed with GS XJG



Ultoxima®
Lapatinib Ditosylate
TABLETS 250mg

Ultoxima® is indicated for the treatment of adult patients with breast cancer, whose tumours overexpress HER2 (ErbB2); • combination with capecitabine for patients with advanced or metastatic disease with progression following prior therapy, which must have included anthracyclines and taxanes and therapy with trastuzumab in the metastatic setting

How does this medication work? What will it do for me?

Lapatinib belongs to the class of medications called antineoplastics (anticancer medications). **It is used in combination with another anticancer medication, capecitabine, to treat advanced or metastatic (cancer that has spread to other parts of the body) breast cancer that is HER2-receptor positive and has progressed despite treatment with other anticancer medications, including trastuzumab. Lapatinib is also used in combination with the medication letrozole, when suitable, for the treatment of metastatic post-menopausal breast cancer in women whose cancer is HER2-receptor positive.**

This medication delays the **progression of breast cancer but does not reduce its symptoms or improve survival. It works by interfering with the growth of certain cancer cells. Your doctor may have suggested this medication for conditions other than those listed in these drug information articles.** As well, some forms of this medication may not be used for all of the conditions discussed here. If you have not discussed this with your doctor or are not sure why you are taking this medication, speak to your doctor. Do not stop taking this medication without consulting your doctor. Do not give this medication to anyone else, even if they have the same symptoms as you do. It can be harmful for people to take this medication if their doctor has not prescribed it.

HOW SHOULD I USE THIS MEDICATION?

LAPATINIB/CAPECTIABINE COMBINATION: THE USUAL DOSE OF LAPATINIB IS 1,250 MG (5 TABLETS) ONCE DAILY. IT SHOULD BE TAKEN AT LEAST 1 HOUR BEFORE OR AT LEAST 1 HOUR AFTER A LOW-FAT MEAL. THE TABLETS SHOULD BE SWALLOWED WHOLE WITH WATER. DO NOT DRINK GRAPEFRUIT JUICE WHILE YOU ARE TAKING THIS MEDICATION.

LAPATINIB/LETROZOLE COMBINATION: THE USUAL DOSE OF LAPATINIB IS 1,500 MG (6 TABLETS) ONCE DAILY. IT SHOULD BE TAKEN AT LEAST 1 HOUR BEFORE OR AT LEAST 1 HOUR AFTER A LOW-FAT MEAL. THE TABLETS SHOULD BE SWALLOWED WHOLE WITH WATER. DO NOT DRINK GRAPEFRUIT JUICE WHILE YOU ARE TAKING THIS MEDICATION.

WHO SHOULD NOT TAKE THIS MEDICATION?

DO NOT TAKE THIS MEDICATION IF YOU ARE ALLERGIC TO LAPATINIB OR ANY INGREDIENTS OF THE MEDICATION OR THE CONTAINER.

Food and Drug Administration (FDA) approved .Prescription Only (POM)
A Taj Pharma™ India Product

DO NOT THROW AWAY ANY MEDICINES VIA WASTEWATER OR HOUSEHOLD WASTE. ASK YOUR PHARMACIST HOW TO THROW AWAY MEDICINES YOU NO LONGER USE. THESE MEASURES WILL HELP PROTECT THE ENVIRONMENT.

TAJ
PHARMA®
A TAJ Enterprise

Take on empty stomach. Swallow whole with water. 1g once daily